Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine

Exclusion Criteria

• •A history of invasive diseases caused by Streptococcus pneumoniae that has been confirmed through cultivation;
• •Known to be allergic to any component of the experimental vaccine, especially those allergic to diphtheria toxoid, or those who previously have a fever of 39.5 ℃ or above after receiving vaccine;
• •History or family history of seizures, epilepsy, encephalopathy, and mental illness;
• •Infants born with abnormal labor processes (difficult labor, instrumental delivery) or with a history of asphyxia or neurological organ damage;
• •A history of confirmed thrombocytopenia or other coagulation disorders may result in contraindications for subcutaneous injection;
• •Injecting human normal immunoglobulin after birth;
• •Known or suspected immunological dysfunction, receiving immunosuppressive therapy (radiation therapy, chemotherapy, corticosteroids, antimetabolites, cytotoxic drugs), such as continuous treatment with systemic corticosteroids (prednisone or similar drugs) for ≥ 14 days, human immunodeficiency virus (HIV) infection, etc;
• •Having congenital malformations, severe malnutrition, developmental disorders, and genetic defects (such as favism);
• •Currently suffering from serious chronic diseases, infectious diseases, active infections, liver diseases, kidney diseases, cardiovascular diseases, and malignant tumors;
• •Severe asthma;
• •Systemic rash, skin ringworm, skin suppuration or blisters;
• •Currently or planning to participate in clinical trials of other drugs in the near future; Researchers believe that any situation that may affect the evaluation of the study.